AR-C78511 exhibited more powerful antiplatelet effects on diabetic platelets than cangrelor (aggregation ratio 36% vs 49%, P<0.05) and greater antithrombotic effects in diabetic rats (P<0.01).
Platelet P2Y12 receptors are overexpressed and constitutively activated in type 2 diabetes, suggesting that P2Y12 inverse agonists like AR-C78511 may offer superior antithrombotic efficacy compared to standard antagonists in this population.
Absolute Event Rate: 36% vs 49%
p-value: p=<0.05
Background: Platelets from patients with diabetes mellitus are hyperactive. Hyperactivated platelets may contribute to cardiovascular complications and inadequate responses to antiplatelet agents in the setting of diabetes mellitus. However, the underlying mechanism of hyperactivated platelets is not completely understood. Methods: We measured P2Y 12 expression on platelets from patients with type 2 diabetes mellitus and on platelets from rats with diabetes mellitus. We also assayed platelet P2Y 12 activation by measuring cAMP and VASP phosphorylation. The antiplatelet and antithrombotic effects of AR-C78511 and cangrelor were compared in rats. Finally, we explored the role of the nuclear factor-κB pathway in regulating P2Y 12 receptor expression in megakaryocytes. Results Platelet P2Y 12 levels are 4-fold higher in patients with type 2 diabetes mellitus compared with healthy subjects. P2Y 12 expression correlates with ADP-induced platelet aggregation (r=0.89, P <0.01). P2Y 12 in platelets from patients with diabetes mellitus is constitutively activated. Although both AR-C78511, a potent P2Y 12 inverse agonist, and cangrelor have similar antiplatelet efficacy on platelets from healthy subjects, AR-C78511 exhibits more powerful antiplatelet effects on diabetic platelets than cangrelor (aggregation ratio 36±3% versus 49±5%, respectively, P <0.05). Using a FeCl 3 -injury mesenteric arteriole thrombosis model in rats and an arteriovenous shunt thrombosis model in rats, we found that the inverse agonist AR-C78511 has greater antithrombotic effects on GK rats with diabetes mellitus than cangrelor (thrombus weight 4.9±0.3 mg versus 8.3±0.4 mg, respectively, P <0.01). We also found that a pathway involving high glucose-reactive oxygen species-nuclear factor-κB increases platelet P2Y 12 receptor expression in diabetes mellitus. Conclusions Platelet P2Y 12 receptor expression is significantly increased and the receptor is constitutively activated in patients with type 2 diabetes mellitus, which contributes to platelet hyperactivity and limits antiplatelet drug efficacy in type 2 diabetes mellitus.
Hu et al. (Thu,) conducted a other in Type 2 diabetes mellitus. AR-C78511 vs. cangrelor was evaluated on Platelet aggregation ratio on diabetic platelets (p=<0.05). AR-C78511 exhibited more powerful antiplatelet effects on diabetic platelets than cangrelor (aggregation ratio 36% vs 49%, P<0.05) and greater antithrombotic effects in diabetic rats (P<0.01).